2. Academic Validation
  3. Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition

  • Cell Rep Med. 2024 Oct 15;5(10):101752. doi: 10.1016/j.xcrm.2024.101752.
Yu Chang 1,  Xiaoju Wang 2,  Jianzhang Yang 3,  Jean Ching-Yi Tien 1,  Rahul Mannan 1,  Gabriel Cruz 1,  Yuping Zhang 1,  Josh N Vo 1,  Brian Magnuson 1,  Somnath Mahapatra 1,  Hanbyul Cho 1,  Saravana Mohan Dhanasekaran 2,  Cynthia Wang 1,  Zhen Wang 4,  Licheng Zhou 3,  Kaijie Zhou 4,  Yang Zhou 5,  Pujuan Zhang 4,  Weixue Huang 4,  Lanbo Xiao 1,  Weihuang Raymond Liu 6,  Rudana Hamadeh 6,  Fengyun Su 1,  Rui Wang 1,  Stephanie J Miner 1,  Xuhong Cao 7,  Yunhui Cheng 1,  Rohit Mehra 8,  Ke Ding 9,  Arul M Chinnaiyan 10
Affiliations

Affiliations

  • 1 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
  • 2 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA.
  • 3 State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China; School of Pharmaceutical Sciences, Jinan University, Guangzhou 511436, People's Republic of China.
  • 4 State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
  • 5 School of Pharmaceutical Sciences, Jinan University, Guangzhou 511436, People's Republic of China.
  • 6 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
  • 7 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA.
  • 8 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA.
  • 9 State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China. Electronic address: dingk@sioc.ac.cn.
  • 10 Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: arul@umich.edu.
PMID: 39353441 DOI: 10.1016/j.xcrm.2024.101752
Abstract

Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Biallelic CDK12 loss has been documented in various malignancies. Here, we develop a selective CDK12/13 PROTAC degrader, YJ9069, which effectively inhibits proliferation in subsets of prostate Cancer cells preferentially over benign immortalized cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. In vivo, YJ9069 significantly suppresses prostate tumor growth. Modifications of YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206, which exhibits comparable efficacy with significantly less toxicity. To identify pathways synthetically lethal upon CDK12/13 degradation, phosphorylation pathway arrays were performed using cell lines treated with YJ1206. Interestingly, degradation or genetic knockdown of CDK12/13 led to activation of the Akt pathway. Targeting CDK12/13 for degradation, in conjunction with inhibiting the Akt pathway, resulted in a synthetic lethal effect in preclinical prostate Cancer Models.

Keywords

AKT; AKT inhibitors; CDK12; CDK13; PROTAC; prostate cancer; proteolysis targeting chimera; synthetic lethality.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z